Generic placeholder image

Current Enzyme Inhibition

Author(s): Gleb Nikolaevich Zyuz’kov*, Larisa Arkad`evna Miroshnichenko, Tatyana Yur`evna Polykova, Elena Vladislavovna Simanina, Alexander Vasil`evich Chayikovskyi and Larisa Yur`evna Kotlovskaya

DOI: 10.2174/1573408019666230816143357

DownloadDownload PDF Flyer Cite As
Insight into JNK Inhibition-based Strategy for the Treatment of Alzheimer's Disease

Page: [51 - 60] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Background: Existing drugs for the treatment of Alzheimer's disease do not meet the basic requirements. Therefore, it is necessary to search for fundamentally new targets for the discovery of drugs for Alzheimer's disease (AD). When creating approaches to stimulate neurogenesis, such a search is promising to conduct as part of the development of a strategy for targeted regulation of intracellular signal transduction in regeneration-competent cells (RCCs). Moreover, the participation of c-Jun Nterminal kinases (JNK) in the regulation of the functions of the nervous tissue and neuroglial cells is known.

Objective: The aim of the work was to study the effect of the JNK inhibitor (IQ-1S) on exploratory behavior and cognitive functions in aged mice (16-month-old male C57BL/6 mice as a model of AD) in combination with the dynamics of shifts in the RCCs functioning (nervous tissue progenitors: neural stem cells (NSCs) and neuronal-committed progenitors (NCPs); neuroglial cells: astrocytes, oligodendrocytes, microglial cells).

Methods: The studies were carried out on male C57BL/6 mice aged 16 months as model of Alzheimer's disease. We studied the effect of the JNK inhibitor on exploratory behavior, conditioned reflex activity, and on the functioning of RCCs in the subventricular zone of the cerebral hemispheres (SVZ). NCPs and neuroglial cells of different types were obtained by immunomagnetic separation.

Results: We observed significant changes in exploratory behavior and impaired conditioned reflex activity in aged C57BL/6 mice. The administration of the JNK inhibitor led to a significant correction of age-related behavioral and memory disorders in aged mice. At the same time, against the background of JNK inhibition-based therapy, an increase in mitotic activity and the content of both NSCs and NCPs in the SVZ was noted. However, these shifts were more pronounced in committed precursors. The phenomenon of the inhibition of NSC specialization under the influence of a pharmacological agent was also revealed. In addition, the JNK inhibitor caused an increase in the secretion of neurotrophic growth factors by oligodendrocytes and microglial cells.

Conclusion: The findings open up prospects for the development of JNK targeting-based approaches for the treatment of AD.

Graphical Abstract

[1]
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet 2021; 397(10284): 1577-90.
[http://dx.doi.org/10.1016/S0140-6736(20)32205-4] [PMID: 33667416]
[2]
Lei P, Ayton S, Bush AI. The essential elements of Alzheimer’s disease. J Biol Chem 2021; 296: 100105.
[http://dx.doi.org/10.1074/jbc.REV120.008207] [PMID: 33219130]
[3]
Guzman-Martinez L, Calfío C, Farias GA, Vilches C, Prieto R, Maccioni RB. New frontiers in the prevention, diagnosis, and treatment of alzheimer’s disease. J Alzheimers Dis 2021; 82(s1): S51-63.
[http://dx.doi.org/10.3233/JAD-201059] [PMID: 33523002]
[4]
Ogbodo JO, Agbo CP, Njoku UO, et al. Alzheimer’s disease: Pathogenesis and therapeutic interventions. Curr Aging Sci 2022; 15(1): 2-25.
[http://dx.doi.org/10.2174/1874609814666210302085232] [PMID: 33653258]
[5]
Zyuz’kov GN, Miroshnichenko LA, Chaikovsky AV, Kotlovskaya LY. Functional state of various types of regenerative-competent neural tissue cells in β-amyloid-induced neurodegeneration. Bull Exp Biol Med 2022; 173(6): 709-13.
[http://dx.doi.org/10.1007/s10517-022-05617-w] [PMID: 36322306]
[6]
Weaver DF. β-Amyloid is an immunopeptide and alzheimer’s is an autoimmune disease. Curr Alzheimer Res 2021; 18(11): 849-57.
[http://dx.doi.org/10.2174/1567205018666211202141650] [PMID: 34856900]
[7]
Zyuz’kov GN, Miroshnichenko LA, Chayikovskyi AV, Kotlovskaya LY. NF-кB: A target for synchronizing the functioning nervous tissue progenitors of different types in Alzheimer’s disease. Curr Mol Pharmacol 2023; 16(2): 234-41.
[http://dx.doi.org/10.2174/1874467215666220601144727] [PMID: 35652396]
[8]
Wegmann S, Biernat J, Mandelkow E. A current view on tau protein phosphorylation in alzheimer’s disease. Curr Opin Neurobiol 2021; 69: 131-8.
[http://dx.doi.org/10.1016/j.conb.2021.03.003] [PMID: 33892381]
[9]
Giacobini E, Cuello AC, Fisher A. Reimagining cholinergic therapy for Alzheimer’s disease. Brain 2022; 145(7): 2250-75.
[http://dx.doi.org/10.1093/brain/awac096] [PMID: 35289363]
[10]
Downey J, Lam JCK, Li VOK, Gozes I. Somatic mutations and Alzheimer’s Disease. J Alzheimers Dis 2022; 90(2): 475-93.
[http://dx.doi.org/10.3233/JAD-220643] [PMID: 36155518]
[11]
Zyuz’kov GN, Miroshnichenko LA, Chaikovsky AV, Kotlovskaya LY. The Role of MARK ERK1/2 and p38 in regulation of functions of neural stem cells and neuroglia under conditions of β-amyloid-induced neurodegeneration. Bull Exp Biol Med 2022; 173(4): 424-8.
[http://dx.doi.org/10.1007/s10517-022-05561-9] [PMID: 36058962]
[12]
Zyuz’kov GN, Miroshnichenko LA, Kotlovskaya LY, Chaikovsky AV. The Role of JAKs and STAT3 in regulation of regenerative-competent cells of the nervous tissue in β-Amyloid-Induced Neurodegeneration. Bull Exp Biol Med 2022; 173(4): 419-23.
[http://dx.doi.org/10.1007/s10517-022-05560-w] [PMID: 36058961]
[13]
Zyuz’kov GN, Miroshnichenko LA, Kotlovskaya LYu, Chayikovskyi AV. Prospect of using ERK1/2 and p38 in regeneration-competent cells of nervous tissue as a drug targets for treating alzheimer’s Disease. Biointerface Res Appl Chem 2022; 13(2): 166.
[http://dx.doi.org/10.33263/BRIAC132.166]
[14]
Zyuz’kov GN, Miroshnichenko LA, Kotlovskaya LYu, Chayikovskyi AV. Inhibitors of intracellular signaling molecules: New horizons in drug discovery for the treatment of Alzheimer’s Disease. Biointerface Res Appl Chem 2023; 13: 1-11.
[http://dx.doi.org/10.33263/BRIAC135.401]
[15]
Zyuz’kov GN. Targeted regulation of intracellular signal transduction in regeneration-competent cells: A new direction for therapy in re-generative medicine. Biointerface Res Appl Chem 2021; 11(4): 12238-51.
[http://dx.doi.org/10.33263/BRIAC114.1223812251]
[16]
Zyuz’kov GN, Miroshnichenko LA, Polykova TY, Simanina EV. Neuroprotective and neuroregenerative effects of shikonin-mediated inhibition of NF-κB/Stat3 in alcoholic encephalopathy. Lett Drug Des Discov 2023; 20(12): 2045-54.
[http://dx.doi.org/10.2174/1570180820666221107112141]
[17]
Zyuz’kov GN, Miroshnichenko LA, Simanina EV, Stavrova LA, Polykova TY. Intracellular signaling molecules of nerve tissue progenitors as pharmacological targets for treatment of ethanol-induced neurodegeneration. J Basic Clin Physiol Pharmacol 2022; 33(3): 305-15.
[http://dx.doi.org/10.1515/jbcpp-2020-0317] [PMID: 33559456]
[18]
Zyuz’kov GN, Miroshnichenko LA, Polyakova TY, Stavrova LA, Simanina EV. Wound healing properties of the protein kinase A inhibitor and the mechanisms of their development. Bangladesh J Pharmacol 2021; 16(2): 34-41.
[http://dx.doi.org/10.3329/bjp.v16i2.50575]
[19]
Zyuz’kov GN, Arkad’evna L, Polykova TY, Simanina EV, Stavrova LA. Targeting cAMP-pathway in Regeneration-competent Cells of Nervous Tissue: Potential to create a novel drug for treatment of ethanol-induced neurodegeneration. Cent Nerv Syst Agents Med Chem 2021; 21(3): 172-80.
[http://dx.doi.org/10.2174/1871524921666210907102847] [PMID: 34493198]
[20]
Zyuz’kov GN, Miroshnichenko LA, Polyakova TYu, Stavrova LA, Simanina EV. Prospects for the use of NF-кb Inhibitors to stimulate the functions of regeneration-competent cells of nerve tissue and neuroregeneration in ethanol-induced neurodegeneration. Biointerface Res Appl Chem 2020; 11(1): 8065-74.
[http://dx.doi.org/10.33263/BRIAC111.80658074]
[21]
Zyuz’kov GN, Miroshnichenko LA, Polyakova TY, et al. Specific features of intracellular signal transduction in the regulation of func-tions of neural stem cells and committed neuronal progenitors. Bull Exp Biol Med 2021; 170(4): 522-7.
[http://dx.doi.org/10.1007/s10517-021-05100-y] [PMID: 33725249]
[22]
Liu Y, Yu M, Jiang D. Downregulation of STAT1 induces the differentiation of neural stem cells through JNK pathway. Tissue Cell 2019; 61: 61-6.
[http://dx.doi.org/10.1016/j.tice.2019.09.004] [PMID: 31759408]
[23]
Wang JL, Chen WG, Zhang JJ, Xu CJ. Nogo-A-Δ20/EphA4 interaction antagonizes apoptosis of neural stem cells by integrating p38 and JNK MAPK signaling. J Mol Histol 2021; 52(3): 521-37.
[http://dx.doi.org/10.1007/s10735-021-09960-6] [PMID: 33555537]
[24]
Zyuz’kov G, Miroshnichenko L, Polyakova T, Simanina E. Potential of using JNK and p53 as novel drug targets for the treatment of alco-holic encephalopathy. Indian J Physiol Pharmacol 2022; 66: 233-40.
[http://dx.doi.org/10.25259/IJPP_163_2022]
[25]
Zyuz’kov GN, Zhdanov VV, Miroshnichenko LA, et al. Role of JNK and p53 in implementation of functions of various types of regener-ation-competent cells of the nervous tissue. Bull Exp Biol Med 2021; 171(3): 333-7.
[http://dx.doi.org/10.1007/s10517-021-05222-3] [PMID: 34297290]
[26]
Jung F, Liu JS, Yang SH, et al. FJU‐C28 inhibits the endotoxininduced pro‐inflammatory cytokines expression via suppressing JNK, p38 MAPK and NF‐κB signaling pathways. Pharmacol Res Perspect 2021; 9(6): e00876.
[http://dx.doi.org/10.1002/prp2.876] [PMID: 34669271]
[27]
Nguyen PL, Bui BP, Duong MTH, Lee K, Ahn HC, Cho J. Suppression of LPS-induced inflammation and cell migration by azelastine through inhibition of JNK/NF-κB Pathway in BV2 Microglial Cells. Int J Mol Sci 2021; 22(16): 9061.
[http://dx.doi.org/10.3390/ijms22169061] [PMID: 34445767]
[28]
Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang Y. TREM2, microglia, and Alzheimer’s disease. Mech Ageing Dev 2021; 195: 111438.
[http://dx.doi.org/10.1016/j.mad.2021.111438] [PMID: 33516818]
[29]
Ahlemeyer B, Halupczok S, Rodenberg-Frank E, Valerius KP, Baumgart-Vogt E. Endogenous murine amyloid-β peptide assembles into aggregates in the aged c57bl/6j mouse suggesting these animals as a model to study pathogenesis of amyloid-β plaque formation. J Alzheimers Dis 2018; 61(4): 1425-50.
[http://dx.doi.org/10.3233/JAD-170923] [PMID: 29376876]
[30]
Kosel F, Pelley JMS, Franklin TB. Behavioural and psychological symptoms of dementia in mouse models of Alzheimer’s disease-related pathology. Neurosci Biobehav Rev 2020; 112: 634-47.
[http://dx.doi.org/10.1016/j.neubiorev.2020.02.012] [PMID: 32070692]
[31]
Nakai T, Yamada K, Mizoguchi H. Alzheimer’s disease animal models: Elucidation of biomarkers and therapeutic approaches for cogni-tive impairment. Int J Mol Sci 2021; 22(11): 5549.
[http://dx.doi.org/10.3390/ijms22115549] [PMID: 34074018]
[32]
Tai LM, Maldonado Weng J, LaDu MJ, Brady ST. Relevance of transgenic mouse models for Alzheimer’s disease. Prog Mol Biol Transl Sci 2021; 177: 1-48.
[http://dx.doi.org/10.1016/bs.pmbts.2020.07.007] [PMID: 33453936]
[33]
Zyuz’kov GN, Zhdanov VV, Miroshnichenko LA, et al. The role of JAK and STAT3 in regulation of secretory function of neuroglial cells of different types in ethanol-induced neurodegenerationt. Bull Exp Biol Med 2022; 172(6): 686-90.
[http://dx.doi.org/10.1007/s10517-022-05457-8] [PMID: 35501646]
[34]
Curtis MJ, Bond RA, Spina D, et al. Experimental design and analysis and their reporting: New guidance for publication in BJP. Br J Pharmacol 2015; 172(14): 3461-71.
[http://dx.doi.org/10.1111/bph.12856] [PMID: 26114403]
[35]
Alvi T, Kumar D, Tabak BA. Social anxiety and behavioral assessments of social cognition: A systematic review. J Affect Disord 2022; 311: 17-30.
[http://dx.doi.org/10.1016/j.jad.2022.04.130] [PMID: 35490878]
[36]
Zufferey V, Vallet PG, Moeri M, et al. Maladaptive exploratory behavior and neuropathology of the PS-1 P117L Alzheimer transgenic mice. Brain Res Bull 2013; 94: 17-22.
[http://dx.doi.org/10.1016/j.brainresbull.2013.01.011] [PMID: 23396115]
[37]
Esquivel N, García Y, Lores B, Gutiérrez M, Rodríguez C. Characterization of aged male BALB/ccenp mice as a model of dementia. Lab Anim Res 2020; 36(1): 7.
[http://dx.doi.org/10.1186/s42826-020-00038-0] [PMID: 32206613]
[38]
de Girolamo P, D’Angelo L. Neurotrophins in the brain of teleost fish: The state of the art. Adv Exp Med Biol 2021; 1331: 289-307.
[http://dx.doi.org/10.1007/978-3-030-74046-7_20] [PMID: 34453307]
[39]
Kumar A, Fontana IC, Nordberg A. Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer’s disease. J Neurochem 2022; 164(3)
[http://dx.doi.org/10.1111/jnc.15565] [PMID: 34931315]
[40]
Zhang X, Wang R, Hu D, et al. Oligodendroglial glycolytic stress triggers inflammasome activation and neuropathology in Alzheimer’s disease. Sci Adv 2020; 6(49): eabb8680.
[http://dx.doi.org/10.1126/sciadv.abb8680] [PMID: 33277246]
[41]
Cai Z, Xiao M. Oligodendrocytes and Alzheimer’s disease. Int J Neurosci 2016; 126(2): 97-104.
[http://dx.doi.org/10.3109/00207454.2015.1025778] [PMID: 26000818]
[42]
Zhao M, Jiang XF, Zhang HQ, et al. Interactions between glial cells and the blood-brain barrier and their role in Alzheimer’s disease. Ageing Res Rev 2021; 72: 101483.
[http://dx.doi.org/10.1016/j.arr.2021.101483] [PMID: 34610479]
[43]
Huang L, Jin J, Chen K, et al. BDNF produced by cerebral microglia promotes cortical plasticity and pain hypersensitivity after peripheral nerve injury. PLoS Biol 2021; 19(7): e3001337.
[http://dx.doi.org/10.1371/journal.pbio.3001337] [PMID: 34292944]
[44]
Chen Y, Colonna M. Microglia in Alzheimer’s disease at single-cell level. Are there common patterns in humans and mice? J Exp Med 2021; 218(9): e20202717.
[http://dx.doi.org/10.1084/jem.20202717] [PMID: 34292312]
[45]
Mangalmurti A, Lukens JR. How neurons die in Alzheimer’s disease: Implications for neuroinflammation. Curr Opin Neurobiol 2022; 75: 102575.
[http://dx.doi.org/10.1016/j.conb.2022.102575] [PMID: 35691251]